^
    Apply
    A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients (NCT02473731)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    08/01/2019
    Initiation :
    10/01/2015
    Primary completion :
    09/22/2016
    Completion :
    10/10/2016
    ERBB3
    |
    CDX-3379
    A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors (NCT02014909)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    07/24/2017
    Initiation :
    01/01/2014
    Primary completion :
    05/25/2017
    Completion :
    06/05/2017
    EGFR • HER-2 • KRAS • BRAF
    |
    HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type
    |
    CDX-3379